Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorMedical University of South Carolina
Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.
Age ≥18 and <60 years
Diagnosis of systemic sclerosis
Presence of sclerodactyly
Ability to provide informed consent
Known hypersensitivity to hyaluronidase
Pregnancy or breastfeeding
Unstable systemic disease
Recent changes in systemic immunomodulatory therapy